Friday - May 9, 2025
MIAMI / Sep 12, 2024 / Business Wire / Ontrak, Inc. (NASDAQ: OTRK), a leading AI-powered and technology-enabled behavioral healthcare company, announced significant findings from the first two-quarters of data collected through its implementation of the Recovering Quality of Life (ReQoL) measure. This patient-reported outcome measure (PROM) assesses the quality of life for individuals with various mental health conditions.
The ReQoL assessment, now a standard component of Ontrak's clinical model, has provided valuable insights into factors impacting mental health across diverse populations. ReQoL assessments are intended to evaluate the impact of mental health conditions, psychological interventions, and healthcare interventions on members’ lives because they focus on understanding the person over the diagnosis, consistent with modern recovery-oriented strategies. Integrating this tool in Ontrak's WholeHealth+ program emphasizes the commitment to measurement feedback in continually improving mental health care and outcomes.
Key Findings:
Dr. Judith Feld, MD, MPH, MMM, Chief Medical Officer at Ontrak Health, commented on the findings: "The ReQoL data results provide us with more nuanced insights into the mental health challenges faced by our members. The ReQoL measure has proven to be a powerful tool for uncovering hidden struggles and tracking clinical progress. Utilizing the ReQoL in our clinical programs has significantly improved the effectiveness of our tech-enabled personalized interventions.”
About Ontrak Health
Ontrak Health (Nasdaq: OTRK) is a leading AI and technology-enabled behavioral healthcare company whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder, and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socioeconomic, medical, and health system barriers that exacerbate the severity of their comorbid illnesses. The company's integrated intervention platform uses AI, predictive analytics, and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
Last Trade: | US$1.57 |
Daily Change: | 0.04 2.61 |
Daily Volume: | 6,747 |
Market Cap: | US$6.630M |
February 19, 2025 November 13, 2024 November 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load